Abstract: Provided are methods and compositions useful in the diagnosis, treatment, and monitoring of osteosarcoma. Antisense to certain microRNA (miRNA) found to be associated with cancer stem cells (CSCs) or tumor-initiating cells (TICs) of osteosarcoma are useful to suppress tumor growth and metastasis, and prolong survival. Antisense oligonucleotides to miR-133a are synergistic in combination with standard chemotherapy such as cisplatin in the treatment of osteosarcoma.
Abstract: Gamma ray and e-beam irradiation provided efficient sterilization of certain self-assembling peptides (including RADA16 in solution) without substantial degradation of the major peptide, while, e.g., another self-assembly peptide, QLEL12 was significantly degraded following irradiation. Irradiation sterilization enhances the rheological property of, for example, RADA16 hydrogel once applied to tissue at a physiological pH. The rheological property increase can result in higher efficacy in a variety of biomedical applications.
Abstract: The present invention to a method, a kit, etc., for predicting the response BNCT using a BSH-related medicine-containing boron preparation and a BPA-containing boron preparation, the method and kit being characterized by examining the expression of CD44, a translation-related factor and/or LAT1 in cancer cells of a sample. When the expression of the CD44 or translation-related factor in the cancer cells of the sample is high, it can be predicted that the BNCT using the BSSH-related medicine-containing boron preparation is likely to be responsive. When the expression of the LAT1 in the cancer cells of the sample is high, it can be predicted that the BNCT using the BPA-containing boron preparation is likely to be responsive.
Abstract: Self-assembling peptides comprising non-ionic polar amino acids for anti-adhesion are provided herein. Compositions, peptide solutions and macroscopic scaffolds of self-assembling peptides consisting essentially of non-ionic, polar amino acids are provided to prevent adhesion or to provide anti-adhesion properties. Particular peptides include those consisting essentially of, serine, threonine, tyrosine, cysteine, glutamine, asparagine, methionine, tryptophan, hydroxy-proline, and combinations thereof. Methods and kits are also provided.
Type:
Grant
Filed:
December 15, 2016
Date of Patent:
March 30, 2021
Assignee:
3-D Matrix, Ltd.
Inventors:
Eun Seok Gil, Marc Rioult, Keiji Nagano, Karl Patrick Gilbert, Toshiro Kiyofuji, Yuya Hasegawa
Abstract: Combination compositions comprising self-assembling peptides and payload agents, and methods of making and using such compositions, are described.
Type:
Grant
Filed:
December 29, 2016
Date of Patent:
October 27, 2020
Assignees:
3-D Matrix, Ltd., Vicus Therapeutics, LLC
Abstract: The enclosed disclosure describes, among other things, a method including the steps of a first deaerating step in which a mixture comprising peptides is deaerated by lowering the pressure, filtering the mixture through a sterilizing filter; and a second deaerating step, in which the filtrate is deaerated by vibration and lowering the pressure.
Abstract: Compositions, peptide solutions and macroscopic scaffolds of self-assembling peptides consisting essentially of non-ionic, polar amino acids are provided. Particular peptides include those comprising or consisting essentially of serine, threonine, tyrosine, cysteine, glutamine, asparagine, methionine, tryptophan, hydroxy-proline, and combinations thereof. Methods of sterilizing the self-assembling peptides, and scaffolds comprising the peptides are also provided.
Type:
Grant
Filed:
December 11, 2015
Date of Patent:
June 16, 2020
Assignee:
3-D Matrix, Ltd.
Inventors:
Eun Seok Gil, Marc Rioult, Keiji Nagano, Karl Partick Gilbert, Toshiro Kiyofuji, Yuya Hasegawa
Abstract: The present disclosure provides peptide compositions (e.g., of self-assembling peptides) with particular attributes (e.g., peptide identity, peptide concentration, pH, ionic strength [including salt identity and/or concentration), etc. that show particularly useful material properties. The present disclosure also provides technologies for selecting and/or formulating particular peptide compositions useful in specific contexts. In some embodiments, provided peptide compositions have an elevated pH within the range of about 2.5 to about 3.5 and/or an ionic strength that is above that of a corresponding composition of the same peptide, at the same concentration, in water, but is below a critical salt point for the peptide (e.g., so that the composition is not cloudy).
Type:
Grant
Filed:
March 10, 2015
Date of Patent:
May 19, 2020
Assignee:
3-D Matrix, Ltd.
Inventors:
Eun Seok Gil, Karl Gilbert, Manav Mehta
Abstract: There is provided a bioabsorbable peptide tissue occluding agent that can be applied to large mammals including humans, the peptide tissue occluding agent being obtained by artificial synthesis to avoid concerns of infection by viruses and the like. The tissue occluding agent contains a peptide, wherein the peptide is an amphiphilic peptide having 8-200 amino acid residues with the hydrophilic amino acids and hydrophobic amino acids alternately bonded, and is a self-assembling peptide exhibiting a ?-structure in aqueous solution in the presence of physiological pH and/or a cation.
Abstract: There is provided a bioabsorbable peptide tissue occluding agent that can be applied to large mammals including humans, the peptide tissue occluding agent being obtained by artificial synthesis to avoid concerns of infection by viruses and the like. The tissue occluding agent contains a peptide, wherein the peptide is an amphiphilic peptide having 8-200 amino acid residues with the hydrophilic amino acids and hydrophobic amino acids alternately bonded, and is a self-assembling peptide exhibiting a ?-structure in aqueous solution in the presence of physiological pH and/or a cation.
Abstract: The invention provides a method and composition for the treatment, prevention, and diagnosis of cancer containing or derived from cancer stem cells.
Type:
Grant
Filed:
January 19, 2017
Date of Patent:
July 2, 2019
Assignees:
3-D Matrix, Ltd., National Cancer Center
Abstract: A syringe and a syringe set are provided. The syringe can be readily distinguished from other syringes only by viewing a tip of the syringe. The syringe includes a tip provided at an end of a barrel body to be filled with a medicine and having an outer diameter of 4.315 mm to 6 mm, a peripheral wall provided around the tip concentrically with the tip, and a helical rib formed on an inner the of the peripheral wall or an outer face of the tip.
Abstract: Materials and methods for treatment of pulmonary bulla are provided. A peptide comprising between about 7 amino acids and about 32 amino acids in a solution may be introduced to a target site. A hydrogel barrier may be provided at the target site in order to treat the pulmonary bulla.